On the track of precision medicine, an AI-driven revolution in gene decoding is accelerating. Recently, Kingmed Diagnostics officially announced that its independently developed cancer pathology gene large model, DeepGEM, has been deployed and put into clinical application. This breakthrough not only elevates the efficiency and accuracy of identifying gene mutations to a new level, but also marks that AI large models are truly entering the frontline of cancer diagnosis and treatment from the laboratory.

DeepGEM's core capability lies in its deep understanding of massive pathology and genetic data. By integrating histological section images, gene sequencing results, and clinical information, the model can predict key oncogenic mutations with unprecedented accuracy, helping doctors quickly identify the "culprits" driving cancer development. The previously time-consuming gene analysis process, which could take days or even weeks, is now significantly shortened with AI assistance, providing patients with precious treatment windows.

MRI Medical (1)

Image source note: The image is AI-generated, and the image licensing service provider is Midjourney.

This deployment was not a solo effort. Kingmed Diagnostics has collaborated with Tencent's AI computing power and algorithm advantages, as well as the clinical resources of the First Affiliated Hospital of Guangzhou Medical University, to jointly build a multimodal large model for pathology gene in real medical scenarios. The collaboration ensures that the technology is not only accurate but also applicable—model outputs directly connect to diagnostic decision-making, enabling personalized treatment plans such as targeted therapy and immunotherapy tailored to each patient.

This progress also reflects Kingmed Diagnostics' strategic depth in the digital transformation of healthcare. As a leading third-party medical testing institution in China, it is upgrading from traditional testing services to an "AI + precision diagnosis" platform. The successful deployment of DeepGEM is not only a technological achievement, but also a critical step in moving medical AI from concept validation to large-scale implementation.

As the model continues to iterate, DeepGEM is expected to further expand into areas such as early screening, prognosis assessment, and drug resistance prediction, promoting cancer prevention and control from "passive treatment" to "active intervention." In today's era of deep integration between AI and gene technology, decoding the "language" of cancer is no longer out of reach—each precise gene interpretation may become a turning point for patients to regain their lives.